scholarly journals Travoprost- and Tafluprost-induced Changes in Intraocular Pressure and Ocular Pulse Amplitude

2021 ◽  
Vol 62 (9) ◽  
pp. 1235-1242
Author(s):  
Gyeong Min Lee ◽  
Seung Joo Ha

Purpose: To compare the intraocular pressure reduction and changes in ocular pulse amplitude of travoprost 0.003% and tafluprost 0.0015%. Methods: We assessed patients who were diagnosed with open-angle glaucoma from January 2017 to July 2019 for the first time at our hospital. Forty-two eyes were assigned to the travoprost group (23 patients) and 26 eyes were assigned to the tafluprost group (14 patients). Changes in intraocular pressure were measured by Goldmann applanation tonometry (GAT), and corrected ocular pulse amplitude (cOPA) was measured using dynamic contour tonometry. Changes in these parameters were observed and compared for 1 year. Results: No significant differences were observed between the GAT measurements and the cOPA of patients treated with travoprost and tafluprost for 1 year (p = 0.512, p = 0.105). The change in initial intraocular pressure on GAT observed after 1 week was -5.32 ± 2.63 mmHg for travoprost and -3.79 ± 3.19 mmHg for tafluprost (p = 0.0457). The initial change in cOPA was +0.04 ± 0.9 mmHg in the travoprost group and -0.76 ± 0.97 mmHg in the tafluprost group (p = 0.0028). Conclusions: Travoprost and tafluprost reached the targeted intraocular pressure with no difference in the long-term effects of reduced intraocular pressure. However, travoprost was initially better at lowering intraocular pressure faster, and tafluprost had a greater effect on lowering OPA. Prostaglandin analogs can be selected individually by considering the aforementioned factors.

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Du Ri Seo ◽  
Seung Joo Ha

Purpose. To compare the ocular pulse amplitude (OPA) lowering effects of preservative-free tafluprost and dorzolamide-timolol fixed combination (DTFC) using dynamic contour tonometry.Methods. In total, 66 eyes of 66 patients with normal tension glaucoma (NTG) (n=34) or primary open angle glaucoma (POAG) (n=32) were included. Patients were divided into two groups: the preservative-free tafluprost-treated group (n=33) and the preservative-free DTFC-treated group (n=33). Intraocular pressure (IOP) was measured using Goldmann applanation tonometry (GAT). OPA was measured using dynamic contour tonometry; corrected OPA (cOPA) was calculated at baseline and at 1 week and 1, 3, and 6 months after treatment.Results. After 6 months of treatment, tafluprost significantly reduced IOP (P<0.001). The OPA lowering effects differed significantly between the two treatment groups (P=0.003). The cOPA-lowering effect of tafluprost (1.09 mmHg) was significantly greater than that of DTFC (0.36 mmHg) after 6 months of treatment (P=0.01).Conclusions. Tafluprost and DTFC glaucoma treatments provided marked OPA and IOP lowering effects. Tafluprost had a greater effect than DTFC; thus, this drug is recommended for patients at risk of glaucoma progression, due to the high OPA caused by large fluctuations in IOP.


2006 ◽  
Vol 31 (10) ◽  
pp. 851-862 ◽  
Author(s):  
Omar S. Punjabi ◽  
Hoai-Ky V. Ho ◽  
Christoph Kniestedt ◽  
Alan G. Bostrom ◽  
Robert L. Stamper ◽  
...  

2009 ◽  
Vol 94 (4) ◽  
pp. 419-423 ◽  
Author(s):  
P. Fogagnolo ◽  
M. Figus ◽  
P. Frezzotti ◽  
M. Iester ◽  
F. Oddone ◽  
...  

Author(s):  
Vincent Libertiaux ◽  
William P. Seigfreid ◽  
Massimo A. Fazio ◽  
Juan F. Reynaud ◽  
Claude F. Burgoyne ◽  
...  

The optic nerve head (ONH) is the site of insult in glaucoma, the second leading cause of blindness worldwide. Intraocular pressure (IOP) is commonly regarded as a major factor in the onset and progression of the disease1 and lowering IOP is the only clinical treatment that has been shown to retard the onset and progression of glaucoma2. However, many patients continue to progress even at an epidemiologically-determined normal level of IOP3. This suggests that in addition to the mean value of IOP, IOP fluctuations could be a factor in glaucomatous pathophysiology. The importance of low frequency fluctuations of clinically-measured mean IOP remains controversial. These studies all rely on snapshot measurements of mean IOP at each time point, and those measurements are taken at relatively infrequent intervals (hourly at the most frequent, but usually monthly or longer). Recently however, there has been some interest in ocular pulse amplitude, or the fluctuation in IOP associated with the cardiac cycle, which can be measured by Dynamic Contour Tonometry (DCT). DCT provides continuous measurement of IOP, but only for a period of tens of seconds in which a patient can tolerate corneal contact without blinking or eye movement, which ironically are two of the most common sources of large high frequency IOP fluctuations according to our telemetric data collected from monkeys4 and previous human studies. In a recent report, continuous IOP telemetry was used in three nonhuman primates to characterize IOP dynamics at multiple time scales for multiple 24-hour periods5.


2007 ◽  
Vol 16 (8) ◽  
pp. 700-703 ◽  
Author(s):  
Jennifer S. Weizer ◽  
Sanjay Asrani ◽  
Sandra S. Stinnett ◽  
Leon W. Herndon

2018 ◽  
Vol 53 (3) ◽  
pp. 215-221 ◽  
Author(s):  
Edsel Ing ◽  
Christian Pagnoux ◽  
Felix Tyndel ◽  
Arun Sundaram ◽  
Seymour Hershenfeld ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document